Latest news with #BSEM
India Today
12-05-2025
- General
- India Today
Manipur Class 10 Result 2025 declared at manresults.nic.in: Direct link to check
The Manipur HSLC Result 2025 has been officially declared. The Board of Secondary Education, Manipur (BSEM) released the Manipur Class 10 results today, May 10, on its official website –- around 3 who appeared for the Class 10 exams can now check their Manipur Board Class 10 result by entering their roll number 37,000 students were waiting eagerly for the Manipur 10th result link to go live. The results were announced through a press conference, followed soon by the activation of the direct result link on the TO CHECK BSEM 10TH RESULT 2025 ONLINE To check your Manipur Board HSLC result, here's what you need to do:Go to on the link that says 'Manipur HSLC Result 2025'Enter your roll number as mentioned in your admit cardClick 'Submit'Your Class 10 result will show up on the screenDownload or print the result for future useDirect link to check Manipur HSLC result 2025WHAT YOUR MANIPUR HSLC 2025 MARKSHEET WILL SHOWThe BSEM 10th Result 2025 will have the following details:Student's name, roll number, and date of birthSubject-wise marks and total marksFinal result status (Pass/Fail)Make sure to keep your Manipur HSLC Admit Card 2025 handy while checking the result. In case of any website delays, wait for a few minutes and try again.
Time of India
12-05-2025
- General
- Time of India
BOSEM Manipur HSLC result 2025 declared: Check class 10 scores at manresults.nic.in
BSEM Manipur HSLC result 2025 released: Check marks and download marksheet at BOSEM Manipur HSLC result 2025: The Board of Secondary Education, Manipur (BOSEM) has officially declared the Manipur High School Leaving Certificate (HSLC) result for 2025. Students who appeared for the Class 10 exams can now check their results on the official BSEM website at . The results were announced on May 12, 2025, and candidates can access their scores by entering their roll number and registration number. The Manipur HSLC 2025 result includes crucial details such as the student's name, roll number, school, division, and marks obtained in individual subjects. Along with the result, the board has issued provisional mark sheets. However, students will need to collect their original marksheets from their respective schools. How to check the BOSEM Manipur HSLC result 2025 online Students can follow these simple steps to check their Manipur HSLC result 2025: Step 1: Visit the official result website at Step 2: Look for the link titled 'Manipur High School Leaving Certificate Examination Result 2025.' Step 3: Click on the link, and a login window will appear. Step 4: Enter your roll number and registration number in the respective fields. Step 5: After entering the details, click on the 'Submit' button. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Invest $200 in Amazon without buying stocks to earn a second salary Marketsall Sign Up Undo Step 6: Your Manipur HSLC result will appear on the screen. Step 7: Download the result and take a printout for future reference. Direct link to check the BOSEM Manipur HSLC result 2025 In the previous year, 2024, a total of 37,547 students appeared for the Manipur HSLC exams. Out of these, 34,931 students successfully passed, giving a pass percentage of 93.03%. The performance of male and female students was quite close. Among the 19,087 male candidates, 18,995 appeared for the exam, with 17,678 passing and a pass percentage of 93.07%. Meanwhile, of the 18,628 female students, 18,552 appeared, with 17,253 passing, resulting in a pass percentage of 93%. For students who did not clear one or two subjects, the BSEM has announced the option to apply for the compartmental exam. Students who wish to appear for the compartmental exams can do so through their respective schools. Important details to check in the result The Manipur HSLC result 2025 provides a comprehensive breakdown of each student's performance. Apart from the overall marks, it includes subject-wise external and internal marks, along with details on the student's division. This will help students better understand their academic performance and areas where improvement is needed. The declaration of the HSLC result marks a significant milestone for the students, and those who have passed can now plan their next steps in education. Students who are not satisfied with their results or need to appear for compartment exams should act quickly to meet the deadlines set by the board. AI Masterclass for Students. Upskill Young Ones Today!– Join Now
Indian Express
12-05-2025
- General
- Indian Express
Manipur HSLC Class 10th Result 2025: How to check scorecard
The Board of Secondary Education Manipur (BSEM) has announced class 10 or High School Leaving Certificate (HSLC) exam results today (May 12). BSEM HSLC exams were held between March 15 and April 3, 2025 in various designated centres throughout the state. Students who appeared for the exam could access the results online at and To help students check the results evenly and without confusion, here is a step-by-step guide: Step 1: Visit the official site – or Step 2: On the website, click the link entitled 'HSLC Exam 2025 Results' Step 3: Enter your roller number and registration number as mentioned on your concession card. Step 4: Click the 'Send' button. Step 5: Your result appears on the screen. Step 6: Download and save the result or take a print for future reference. Students are strongly recommended to maintain the admission card while checking the results and ensuring a stable internet connection to avoid delay. In the case of non conformity or technical problems, they should contact school employees or BSEM aid line. The board will also provide details on reassessment, switching and exit exams shortly after the result is released. Wish all students waiting for the results! In addition to checking the online results, students can also reach their digital brand sheet through the Digilokar platform, when the fold uploads them. These digital certificates are legally valid and can be used for recording and verification purposes. Students are encouraged to register on Digilokar by using the Aadhaar number and their mobile number to reach their brand sheet.
Yahoo
31-03-2025
- Business
- Yahoo
BioStem Announces Notice of Allowance for Two U.S. Patent Applications
Company continues to innovate and strengthen its patent portfolio with 43 issued patents and 26 pending for its advanced wound care technology POMPANO BEACH, Fla., March 31, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for two of BioStem's patent applications. Jason Matuszewski, Chief Executive Officer of BioStem, stated: 'BioStem is actively expanding its patent portfolio to accelerate product innovation and to drive development of new products that continue to elevate the standards of wound care. These newly granted patents will play a pivotal role in the development of next-generation products, further solidifying our position as a leader in the industry. BioStem's robust intellectual property portfolio spans the wound care landscape, providing strong protection as we continue to introduce breakthrough solutions to the market and consider other regulatory pathways to strengthen our product positioning." The USPTO has issued a Notice of Allowance for the following applications: No. 18/593,225: MICRONIZED COMPOSITIONS FOR WOUND HEALING PREPARED FROM INTACT HUMAN AMNION-CHORION TISSUE HAVING AN INTACT INTERMEDIATE SPONGY LAYER POSITIONED THERE BETWEEN The patent is directed to novel and inventive micronized human placental compositions for wound care. The unique method of preparing BioStem's compositions results in optimal retention of the structural and molecular profile of the amnion and chorion tissue. These compositions can be used to develop products for wound packing, treatment of wounds having irregular surfaces/boundaries, weeping wounds, and dental/ oral wounds. These micronized compositions could even be integrated into a therapeutic bandage to support healing of a topical wound. No. 18/290,914: STERILE HUMAN PLACENTAL ALLOGRAFTS AND METHODS OF MAKING THEREOF The patent is directed to novel and inventive human placental allograft compositions manufactured with the BioRetain® process. The unique method of preparing these allograft compositions results in optimal retention of the structural and molecular profile of the amnion and chorion tissue thereby facilitating and supporting wound treatment when compared with conventional human placental allografts for the treatment of, for example, diabetic foot ulcers, dental wounds, and/or other topical wounds. Mr. Matuszewski added: 'The added protection for our proprietary BioREtain processing method bolsters the differentiation of this technology in the marketplace. We also intend to demonstrate the benefits of those differences to patients with ongoing benchtop and clinical studies.' Join BioStem's Distribution List & Social Media: To follow the latest developments at BioStem, sign-up to the Company's email distribution list HERE, and follow us on X and LinkedIn. About BioStem Technologies, Inc. (OTC: BSEM):BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioREtain® processing method. BioREtain® has been developed by applying the latest research in advanced wound care, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies' quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks ('AATB'). These systems and procedures are established per current Good Tissue Practices ('cGTP') and current Good Manufacturing Processes ('cGMP'). Our portfolio of quality brands includes AmnioWrap2 ™, VENDAJE®, VENDAJE AC®, and VENDAJE OPTIC®. Each BioStem Technologies placental allograft is processed at the Company's FDA registered and AATB accredited site in Pompano Beach, Florida. For more information visit and follow us on X and LinkedIn. Forward-Looking Statements:Except for statements of historical fact, this release also contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts of future events. Forward-looking statements may be identified using words such as 'forecast,' 'intend,' 'seek,' 'target,' 'anticipate,' 'believe,' 'expect,' 'estimate,' 'plan,' 'outlook,' and 'project' and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements with respect to the operations of the Company, strategies, prospects and other aspects of the business of the Company are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from expectations expressed or implied by such forward-looking statements. These factors include, but are not limited to: (1) the impact of any changes to the reimbursement levels for the Company's products; (2) the Company faces significant and continuing competition, which could adversely affect its business, results of operations and financial condition; (3) rapid technological change could cause the Company's products to become obsolete and if the Company does not enhance its product offerings through its research and development efforts, it may be unable to effectively compete;(4) to be commercially successful, the Company must convince physicians that its products are safe and effective alternatives to existing treatments and that its products should be used in their procedures; (5) the Company's ability to raise funds to expand its business; (6) the Company has incurred significant losses since inception and may incur losses in the future; (7) changes in applicable laws or regulations; (8) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; (9) the Company's ability to maintain production of its products in sufficient quantities to meet demand; and (10) the COVID-19 pandemic and its impact, if any, on the Company's fiscal condition and results of operations; You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Although it may voluntarily do so from time to time, the Company undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. BioStem Technologies, 954-380-8342 Website: info@ @BSEM_TechFacebook: BioStemTechnologies PCG AdvisoryAdam Holdsworth Phone: 917-497-9287 Email: adam@ in to access your portfolio
Yahoo
24-02-2025
- Health
- Yahoo
BioStem Receives Institutional Review Board (IRB) Approval to Advance Clinical Trial Demonstrating the Therapeutic Benefits of BioREtain® Technology in Treating Venous Leg Ulcers
Study comparing BioStem's proprietary amnion chorion allograft versus the standard of care aims to demonstrate superior outcomes, further validating its clinical efficacy to support market expansion POMPANO BEACH, Fla., Feb. 24, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, announces Institutional Review Board (IRB) approval for a clinical study to evaluate its proprietary BioREtain® Amnion Chorion (BR-AC) for the treatment of venous leg ulcers (VLU). This study aims to assess the efficacy of BR-AC compared to standard of care in patients with non-healing VLUs, providing critical data to support continued market adoption of its proprietary technology. Jason Matuszewski, CEO of BioStem, stated: "This is our third prospective clinical trial across various wound indications, and we continue to advance these trials for our allograft products with the goal of demonstrating clinical superiority for healthcare professionals and payers. We previously announced the publication of a peer-reviewed study demonstrating breakthrough results with the application of this product for diabetic foot ulcers. BioStem is confident that the benefits of our technology will become evident in additional indications such as VLUs and looks forward to providing updates as the trial progresses.' About BioREtain®: BioStem's allografts are processed utilizing the Company's proprietary BioREtain® method, which retains the tissue's native properties while maintaining the structure and matrix found in fresh perinatal tissue. The patented six-step BioREtain® process is gentle, minimally invasive, and preserves the natural integrity of the amniotic tissue/ components critical to wound treatment. For a full overview of BioREtain, please visit: HERE. BR-AC consists of unseparated amnion and chorion membranes, including the intact intermediate layer. It contains collagen, extracellular matrix, and a wide array of protein components including growth factors, cytokines, and chemokines. BR-AC is a minimally manipulated dehydrated tissue allograft that serves as a protective covering for soft tissue wounds. BR-AC-VLU Clinical Trial Overview and Design: Title: Non-healing Venous Leg Ulcers Treated with Standard Care, With or Without BR-AC Primary Outcome Measures: The primary objective of this study is to assess whether the addition of BR-AC increases the likelihood of achieving complete wound closure in venous leg ulcers (VLUs) compared to standard of care alone. The study will evaluate the proportion of subjects who achieve full wound closure, defined as 100% re-epithelialization, over a 12-week treatment period. Link: HEREThe BR-AC-VLU trial is a multicenter, randomized, controlled study that will enroll at least 60 subjects with a non-healing VLU at approximately 15 sites across the United States. The study will focus on a patient population with non-healing, non-infected VLUs having confirmed venous reflux by duplex Doppler ultrasound. All consented subjects will enter a two-week run-in period receiving only standard wound care. Those who comply with compression therapy, have not healed greater than 30% and continue to meet criteria after two-weeks will be randomized in a 1:1 fashion. Weekly study visits will be conducted to monitor compliance with wound care protocols and compression therapy, as well as to document when wound closure is achieved. A follow-up phase will commence for all subjects that achieve complete wound closure, which is designed to measure longevity and durability of the closed wound. This follow-up will consist of a four-week period with two visits at each two-week interval. Venous Leg Ulcers Facts: Venous leg ulcers are chronic sores that develop on the legs due to poor blood flow in the veins and affect up to two million people in the United States annually. The venous leg ulcer market, focused on the treatment and management of these ulcers, is growing at a CAGR of more than 4%, driven by the growing prevalence of this condition, increasing awareness about treatment options, and advancements in wound care technologies like compression therapies and bioengineered dressings. The market is projected to see significant growth due to the aging population and rising chronic disease rates, with estimates suggesting a market size reaching several billion dollars in the coming years. Join BioStem's Distribution List & Social Media:To follow the latest developments at BioStem, sign-up to the Company's email distribution list HERE, and follow us on Twitter and LinkedIn. About BioStem Technologies, Inc. (OTC: BSEM):BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioREtain® processing method. BioREtain® has been developed by applying the latest research in advanced wound care, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies' quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks ('AATB'). These systems and procedures are established per current Good Tissue Practices ('cGTP') and current Good Manufacturing Processes ('cGMP'). Our portfolio of quality brands includes AmnioWrap2™, VENDAJE®, VENDAJE AC®, and VENDAJE OPTIC®. Each BioStem Technologies placental allograft is processed at the Company's FDA registered and AATB accredited site in Pompano Beach, Florida. For more information visit and follow us on Twitter and LinkedIn. Forward looking StatementsExcept for statements of historical fact, this release also contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts of future events. Forward-looking statements may be identified using words such as 'forecast,' 'intend,' 'seek,' 'target,' 'anticipate,' 'believe,' 'expect,' 'estimate,' 'plan,' 'outlook,' and 'project' and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements with respect to the operations of the Company, strategies, prospects and other aspects of the business of the Company are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from expectations expressed or implied by such forward-looking statements. These factors include, but are not limited to: (1) the impact of any changes to the reimbursement levels for the Company's products; (2) the Company faces significant and continuing competition, which could adversely affect its business, results of operations and financial condition; (3) rapid technological change could cause the Company's products to become obsolete and if the Company does not enhance its product offerings through its research and development efforts, it may be unable to effectively compete; (4) to be commercially successful, the Company must convince physicians that its products are safe and effective alternatives to existing treatments and that its products should be used in their procedures; (5) the Company's ability to raise funds to expand its business; (6) the Company has incurred significant losses since inception and may incur losses in the future; (7) changes in applicable laws or regulations; (8) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; (9) the Company's ability to maintain production of its products in sufficient quantities to meet demand; and (10) the COVID-19 pandemic and its impact, if any, on the Company's fiscal condition and results of operations; You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Although it may voluntarily do so from time to time, the Company undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. BioStem Technologies, 954-380-8342 Website: info@ @BSEM_TechFacebook: BioStemTechnologies PCG AdvisoryJeff Ramsonjramson@ in to access your portfolio
